Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation

Amy M. Sainski,1,3 Haiming Dai,2 Sekar Natesampillai,3 Yuan-Ping Pang,1 Gary D. Bren,2 Nathan W. Cummins,3 Cristina Correia,2 X. Wei Meng,1,2 James E. Tarara,5 Marina Ramirez-Alvarado,5 David J. Katzmann,5 Christina Ochsenbauer,4 John C. Kappes,4 Scott H. Kaufmann,1,2 and Andrew D. Badley3,6

1Department of Molecular Pharmacology and Experiment Therapeutics, 2Division of Oncology Research, 3Division of Infectious Diseases, and 4Department of Medicine, University of Alabama, Birmingham, AL 35294
2Department of Biochemistry and Molecular Biology and 5Department of Molecular Medicine, Mayo Clinic, Rochester MN 55905

Previous studies have shown that human immunodeficiency virus (HIV) protease cleaves procaspase 8 to a fragment, termed Casp8p41, that lacks caspase activity but nonetheless contributes to T cell apoptosis. Herein, we show that Casp8p41 contains a domain that interacts with the BH3-binding groove of pro-apoptotic Bak to cause Bak oligomerization, Bak-mediated membrane permeabilization, and cell death. Levels of active Bak are higher in HIV-infected T cells that express Casp8p41. Conversely, targeted mutations in the Bak-interacting domain diminish Bak binding and Casp8p41-mediated cell death. Similar mutations in procaspase 8 impair the ability of HIV to kill infected T cells. These observations support a novel paradigm in which HIV converts a normal cellular constituent into a direct activator that functions like a BH3-only protein.

Introduction

Apoptosis reflects the interplay between three groups of proteins: caspases, inhibitor of apoptosis (IAP) proteins, and Bcl-2 family members (Taylor et al., 2008; Strasser et al., 2011). Caspases play two previously recognized roles in this process (Earnshaw et al., 1999; Taylor et al., 2008), transducing signals such as death receptor ligation or mitochondrial cytochrome c release into protease activity (initiator caspases) and cleaving a wide variety of cellular constituents to yield the apoptotic phenotype (effector caspases). Some of these cysteine proteases are inhibited by X chromosome–linked IAP (Taylor et al., 2008; Fulda and Vucic, 2012). Moreover, Bcl-2 family members regulate the mitochondrial cytochrome c release that initiates caspase 9 activation. In particular, the proapoptotic Bcl-2 family members Bax and Bak, which are responsible for mitochondrial outer membrane (MOM) permeabilization (MOMP), are inhibited by binding to antiapoptotic family members such as Bcl-2 and Mcl-1, and are activated by BH3-only proteins through either direct interactions (Kim et al., 2009; Gavathiotis et al., 2010; Dai et al., 2011; Czabotar et al., 2013) or neutralization of antiapoptotic family members (Llambi et al., 2011; Strasser et al., 2011).

Viruses have evolved several strategies for impacting cellular apoptotic pathways. These include the expression of IAP proteins such as Op-IAP and antiapoptotic Bcl-2–like proteins such as Epstein-Barr virus BHLF1 (Miller, 1999; Galluzzi et al., 2008). Indeed, study of these proteins has informed current understanding of viral pathogenicity as well as apoptotic pathway regulation. HIV, however, has not previously been shown to impact the core apoptotic machinery directly.

HIV causes death of infected CD4 T cells in three different ways: by triggering pyroptosis during abortive infection (Doitsh et al., 2010), activating an integrase-initiated DNA damage response in cells that integrate the virus (Cooper et al., 2013), or inducing apoptosis in cells that are productively infected, i.e., that produce progeny virions. During HIV production, HIV protease is active in the cytoplasm and at the cell membrane (Kaplan et al., 1994), where it cleaves both viral and host substrates (Ventoso et al., 2001). Moreover, expression of HIV protease is known to induce apoptosis (Baum et al., 1990; Blanco et al., 2003), although the process also...
requires procaspase 8 (Nie et al., 2002; Nie et al., 2008). Curiously, procaspase 8 is directly cleaved by HIV-1 protease between F355 and F356, generating a 41-kD N-terminal fragment, termed Casp8p41, that lacks the catalytic cysteine of an active caspase (Nie et al., 2002; Nie et al., 2008). Nonetheless, protease inhibitor–resistant HIV isolates that replicate but do not cause CD4 T cell decline in patients (discordant responses) contain HIV protease variants that are impaired in their ability to generate Casp8p41 (Natesampillai et al., 2010), which indicates the importance of Casp8p41 in T cell demise during productive HIV infection. Further studies have shown that Casp8p41 traffics to mitochondria (Algeciras-Schimnich et al., 2007; Sainski et al., 2011) and requires procaspase 9 to induce apoptosis (Sainski et al., 2011). How Casp8p41, as a catalytically inactive caspase fragment, activates caspase 9 to induce apoptosis has remained unclear.

In the present study, we show that Casp8p41 binds the Bak BH3-binding groove, leading to Bak oligomerization, Bak-mediated MOMP, and cell death. These observations not only provide new insight into the mechanism of T cell death during productive HIV infection, but also suggest a new paradigm in which a protein that ordinarily does not bind Bel-2 family members can be converted into a direct activator to affect apoptosis.

**Results and discussion**

**Casp8p41-induced death requires Bak**

To gain mechanistic insight into Casp8p41-mediated killing, we screened for lentiviral shRNAs that diminish Casp8p41-induced cell death (Fig. S1 A). Because EGFP-Casp8p41 induces death within 24 h (Sainski et al., 2011), cells expressing both EGFP-Casp8p41 and RFP from the shRNA constructs at 48 h must have been altered in a way that renders Casp8p41 less toxic. Of 27,000 shRNAs tested, 1,558 were at least threefold higher in RFP/EGFP double-positive cells compared with background. Of these overrepresented shRNAs, only three (FADD, procaspase 9, and Bak) target proapoptotic components of the core apoptotic machinery. Because procaspase 9, which is involved in HIV-induced T cell death (Sainski et al., 2011), is downstream of mitochondria (Earnshaw et al., 1999; Taylor et al., 2008), we focused on FADD and Bak. Casp8p41 induced similar levels of apoptosis in FADD-deficient and parental Jurkat cells (unpublished data). In contrast, siRNA-mediated Bak knockdown diminished Casp8p41 killing, which indicates an important role for Bak in Casp8p41-induced death (Fig. S1, B and C).

**Casp8p41 binds Bak**

Based on the observation that Casp8p41, like a BH3-only protein, translocates to mitochondria while inducing apoptosis (Algeciras-Schimnich et al., 2007; Sainski et al., 2011), we assessed the possibility that Casp8p41 and Bak might directly interact. For these studies we initially immobilized recombinant His-tagged Bak lacking the transmembrane domain (His6 BakΔTM) on a surface plasmon resonance (SPR) chip and assessed binding of GST-Casp8p41. Binding occurred in a dose-dependent manner, with an equilibrium dissociation constant (KD) of 16 ± 5 nM (Fig. 1, A and C; and Fig. S2 A), which is tighter than BakΔTM binding to Bim under comparable conditions (Dai et al., 2011). In contrast, full-length procaspase 8 fused to GST-bound BakΔTM 100-fold less tightly (Fig. 1, B and C; and Fig. S2 B), potentially explaining why full-length procaspase 8 does not independently induce apoptosis.

**Casp8p41 contains a latent Bak activator domain**

Using protein threading (Wu and Zhang, 2008) and multiple molecular dynamic simulations (57 independent 10-ns simulations with a time step of 1 fs) performed according to published protocols (Dai et al., 2011; Pang et al., 2012), we generated a three-dimensional model of Casp8p41 in order to gain insight into residues of Casp8p41 involved in the interaction with Bak. This model suggested that amino acids 141–160 of Casp8p41 adopt a loop conformation in their free state and an α-helical conformation when bound to the Bak BH3-binding groove (Fig. 2, A and B). Even though this Casp8p41 region exhibits only 35% sequence similarity to classical BH3 domains, the spatial positions of residues critical for Bak binding resemble those of a BH3 domain (Fig. 2 A, bottom). In contrast, in full-length procaspase 8, amino acids 141–160 are buried beneath the C-terminal domain, which folds back on the rest of the protein (Yu et al., 2009). Thus, the ability of HIV-1 protease to proteolytically remove the procaspase 8 C terminus, exposing a loop we term the “latent Bak activator domain” in Casp8p41, accounts for the preferential binding of Casp8p41 but not procaspase 8 to Bak.

---

**Figure 1. Casp8p41 binds Bak.** (A) Binding of 50–800 nM GST-Casp8p41 to immobilized His6-BakΔTM as assessed by SPR. Representative of n = 3. (B) His6-BakΔTM immobilized on an SPR chip was exposed to 400 nM GST-Casp8p41 or GST–procaspase 8. Representative of n = 3. (C) Summarized results from three independent experiments (*, P < 0.05). Error bars indicate SD.
Figure 2. The latent Bak activator domain in Casp8p41 interacts with the BH3-binding groove in Bak. (A) Sequence alignment of Bim BH3, Puma BH3, Noxa BH3, and Casp8p41. Multiple molecular dynamics simulations revealed that the three BH3 domains form an α-helix in the Bak BH3-binding groove. Key interactions of the three BH3 domains with the Bak groove involving two hydrophobic residues are highlighted in green (e.g., L141Puma and L148Puma) and one anionic residue in red (e.g., D146 Puma). Residues of the latent Bak activator domain spatially approximate these critical BH3 domain residues. (B) Close-up view of the multiple molecular dynamics simulation-refined model of the activator domain of Casp8p41 (green) binding the Bak BH3-binding groove. (C) Immobilized GST-Casp8p41 was exposed to 125 nM His6-Bak127E or His6-Bak127E R127E. Representative of n = 3. (D) SPR analysis of GST fused to Casp8p41, Casp8p41 V150A/L157A, or Casp8p41 V150E/L157K binding to immobilized His6-Bak127E. Representative of n = 3. (E) Summarized results from three independent experiments (**, P < 0.01). (F) Peptides used in (G) and (H). (G) Immobilized His6-Bak127E was exposed to 400 nM Casp8p41 latent Bak activator peptide, Bim BH3 peptide, or Casp8p41 N-terminal peptide. Representative of n = 3. (H) Summarized results from three independent experiments (***, P < 0.001). (I) Pull-downs from 293T cells transfected with empty vector, HA-Casp8p41, HA-Casp8p41 V150A/L157A, or HA-Casp8p41 V150E/L157K along with S peptide–Bak (left) or S peptide–empty vector (right). Representative of n = 4. Error bars indicate SD.
Figure 3. Casp8p41 facilitates Bak oligomerization and Bak-mediated MOMP. (A) Dextran-FITC–loaded liposomes composed of MOM lipids were incubated with 50 nM His6-BakΔTM in the absence or presence of 200 nM GST, GST-Casp8p41, or GST-Casp8p41 V150E/L157K at 37°C for 30 min. Bim BH3 peptide served as a positive control. After bismaleimidohexane cross-linking, samples were subjected to SDS-PAGE and blotted for Bak. (B) After
Further simulations predicted that Val\textsuperscript{150} and Leu\textsuperscript{157} in the latent Bak activator domain of Casp8p41 (Fig. 2, A and B) dock in two previously described hydrophobic holes in the Bak BH3 binding groove (Dai et al., 2011; Pang et al., 2012). To test this model, we mutated residues in Bak or Casp8p41 predicted to be critical for the interaction. When Bak Arg\textsuperscript{127}, a conserved residue in the BH3-binding grooves of all Bcl-2 family members (Dai et al., 2011), was mutated to Glu, Casp8p41 binding diminished markedly (Fig. 2 C), which implicates the Bak BH3-binding groove in Casp8p41 binding. Likewise, Casp8p41 V150E/L157K bound Bak much less tightly than wild type (wt) Casp8p41 (K\textsubscript{d} = 400 ± 80 nM vs. 19 ± 3 nM; Fig. 2, D and E; and Fig. S2 C), highlighting the importance of the latent Bak activator domain in this binding. In contrast, a more conservative Casp8p41 V150A/L157A mutant, which was predicted by the simulations to maintain affinity for Bak, bound indistinguishably from the wt construct (K\textsubscript{d} = 22 ± 5 nM vs. 19 ± 3 nM; Fig. 2, D and E; and Fig. S2 D).

To further confirm that the latent Bak activator domain is responsible for Bak binding, a synthetic peptide consisting of amino acids 130–160 of procaspase 8 (Bak activator peptide, Fig. 2 F) was also examined. Binding of the synthetic Bak activator peptide to immobilized Bak (Fig. 2, G and H) was similar to that of full-length Casp8p41 (Fig. 1, B and C) and tighter than binding of synthetic BH3 peptide (Fig. 2, G and H). In contrast, a control peptide from the Casp8p41 N-terminal domain (Fig. 2 F) failed to bind Bak at all (Fig. 2, G and H).

To assess the ability of Casp8p41 and Bak to interact in intact cells, Bak and wt or mutant Casp8p41 constructs were expressed in HEK 293T cells. Despite the transient nature of BH3 peptide–Bak interactions (Dai et al., 2011), small amounts of Bak could be pulled down with Casp8p41 and the V150A/L157A mutant but not the Casp8p41 V150E/L157K mutant (Fig. 2 I).

Collectively, the results in Fig. 2 identify Casp8p41 residues 130–160 as a peptide that binds the BH3-binding groove of Bak in vitro and in intact cells.

Casp8p41 binding to Bak causes Bak activation

Based on recent studies showing that binding to activator domain only proteins such as Bim and truncated Bid induces Bak oligomerization and membrane permeabilization (Dai et al., 2011; Moldoveanu et al., 2013), we assessed whether Casp8p41 activates Bak. When His\textsubscript{8}-Bak was incubated with liposomes composed of MOM lipids, cross-linked with bismaleimidohexane, subjected to SDS-PAGE, and blotted for Bak, Casp8p41 induced Bak oligomerization, as indicated by readily detectable Bak dimers, whereas Casp8p41 V150E/L157K induced less dimerization (Fig. 3 A). Size exclusion chromatography demonstrated that Casp8p41 also induced higher-order Bak oligomers (Fig. 3 B).

When release of FITC-labeled dextran from liposomes composed of MOM lipids was assessed (Kuwana et al., 2005; Dai et al., 2011), Casp8p41 had no effect on these liposomes by itself but nonetheless increased Bak-mediated release (Fig. 3, C and D). In contrast, Casp8p41 V150E/L157K, which exhibits diminished Bak binding (Fig. 2, D and E) and oligomerization (Fig. 3 A), induced no additional FITC-dextran release above that seen with GST alone (Fig. 3 E). Likewise, Casp8p41 increased the ability of Bak to release cytochrome c from mitochondria, whereas Casp8p41 V150E/L157K did not (Fig. 3, G and I). Importantly, this MOMP depended on the presence of Bak in mitochondria and was not observed in mitochondria from Bak\textsuperscript{−/−} or Bax\textsuperscript{−/−}Bak\textsuperscript{−/−} cells (Fig. 3, H and J).

In additional experiments, we tracked Bak activation using a well-described conformation-sensitive antibody. Like Jurkat cells treated with agonistic anti-Fas antibody (Fig. 4 A), cells transfected with EGFP-Casp8p41 exhibited increased binding of this antibody (Fig. 4 B). Casp8p41-positive peripheral blood mononuclear cells from viremic HIV-infected patients also displayed increased binding of the activation-sensitive anti-Bak antibody relative to Casp8p41-negative cells from the same patients (Fig. 4, C and D).

Collectively, these results indicate that Casp8p41 induces Bak oligomerization and enhances Bak-mediated MOMP, leading to cytochrome c release in vitro, whereas Casp8p41 V150E/L157K is impaired in these functions. Moreover, the presence of Casp8p41 tracks with the activated Bak conformation in vitro and in vivo.

Mutations in the latent Casp8p41 Bak activator domain impair killing by HIV

If these observations are pertinent to Casp8p41-mediated killing, the V150E/L157K mutation should diminish apoptosis, whereas the V150A/L157A mutation with preserved Bak binding should not. To test these predictions, we initially transfected plasmids encoding wt EGFP-Casp8p41, the V150A/L157A mutant, or the V150E/L157K mutant into Jurkat T cells and assessed death by annexin V binding 6 h later. Wt Casp8p41 killed 36% of the cells in which it was expressed, and Casp8p41 V150E/L157K killed fewer cells (17%, P < 0.05 vs. wt), whereas Casp8p41 V150A/L157A induced killing similar to wt (28%, P > 0.05 vs. wt; Fig. 5, A and C). Similar results were observed at different time points (Fig. S3 A) and when death was assessed by TUNEL (Fig. 5, B and D). Despite these differences in killing, all Casp8p41 variants trafficked to mitochondria normally (Fig. S3, B and C).
In further experiments, procaspase 8–deficient Jurkat I9.2 cells were transfected with empty vector or plasmids encoding EGFP fused to various procaspase 8 constructs and subsequently infected with vesicular stomatitis virus (VSV) pseudotyped HIV-1 reporter virus (HXB, Δvpu, Δvpr). Viral replication in the various transfected (EGFP+) cells was similar (Fig. S3, E–G). When viability of the transfected (EGFP+) cells was assessed on day 3 after HIV infection, procaspase 8–deficient cells sustained negligible death (82% viable), whereas cells expressing EGFP fused to wt procaspase 8 or the C360S (catalytically inactive) mutant were killed equally (35% and 38% viable, respectively; Fig. 5 E), which confirms that procaspase 8 is required for HIV-induced killing but that caspase 8 catalytic activity is not (Algeciras-Schimnich et al., 2007; Nie et al., 2008).

Consistent with the protein binding data, HIV-induced killing was diminished in cells expressing EGFP–procaspase 8 V150E/L157K compared with the wt construct (61% vs. 35% viable on day 3, P = 0.005; Fig. 5 F). Not surprisingly, HIV-induced killing was not completely eliminated by the V150E/L157K mutation, as other HIV-encoded proteins known to induce cell death such as Tat and nef are still expressed, and infected cell killing by activation of the DNA damage response or accumulation of reverse transcripts can still occur (Doitsh et al., 2010; Cooper et al., 2013). Nonetheless, the decrease in cell killing when HIV-producing cells express EGFP–procaspase 8 V150E/L157K at levels similar to wt EGFP–procaspase 8 (Fig. S3 D) demonstrates that HIV-induced death depends substantially upon the ability to generate Casp8p41 that can bind the Bak BH3-binding groove. Consistent with this conclusion, EGFP–procaspase 8 V150A/L157A, which generates Casp8p41 V150A/L157A that binds Bak almost as strongly as wt Casp8p41 (Fig. 2), supports death of infected cells at a rate that approaches that of cells expressing wt procaspase 8 (Fig. 5 F, 48% vs. 35% viable, P = 0.09).

Collectively, these observations suggest a novel and unexpected mechanism by which Casp8p41, a catalytically inactive caspase fragment, activates the mitochondrial apoptotic pathway. In particular, our results show for the first time that Casp8p41 interacts with Bak to induce Bak oligomerization, Bak-induced MOMP, and Bak-mediated T cell killing (Figs. 1, 3, and 5). Further experiments have traced the Casp8p41–Bak interaction to a domain in Casp8p41 that is unmasked when the C-terminal end of procaspase 8 is removed by HIV protease (Fig. 2). Importantly, a synthetic peptide containing this activator domain binds to Bak (Fig. 2, G and H) as tightly as Casp8p41 and >100-fold more tightly than full-length procaspase 8 (Fig. 1 B and Fig. S2). Moreover, the latent Bak activator domain in Casp8p41, like the BH3 domain of Bim, binds the BH3-binding groove of Bak (Fig. 2 G) to trigger subsequent events. Further, charge-altering mutation of two critical residues in the activator domain markedly diminishes binding of Casp8p41 to Bak ex vivo (Fig. 2, D and E) as well as T cell killing by Casp8p41 (Fig. 5, A–D) or HIV (Fig. 5 F), which confirms the importance of the Casp8p41-induced Bak activation mechanism described here.

These results have important implications for understanding HIV-induced T cell death. Although HIV-1 can undoubtedly kill both infected and bystander CD4 T cells via multiple mechanisms, our observation that killing of productively infected cells is diminished by critical mutations in the Casp8p41 activator domain (Fig. 5 F) suggests that Casp8p41 plays a prominent role in the death of cells productively infected with HIV. These results also provide an explanation for the clinical observation that impaired Casp8p41 production is associated with smaller declines in CD4+ cell counts (Natesampillai et al., 2010).

The present observation that a domain of a non–Bcl-2 family member generated or unmasked during cell signaling can serve as a direct activator to trigger mitochondrial apoptosis also provides a new paradigm in apoptotic regulation. Previous studies of Bax and Bak activation have focused exclusively on the role of BH3-only proteins (Cheng et al., 2001; Letal et al., 2002; Walensky et al., 2006; Dai et al., 2011; Lambi et al., 2011; Czabotar et al., 2013; Moldoveanu et al., 2013). Our observation that proapoptotic Bak can be directly activated by Casp8p41 raises a question of whether similar unmasking of latent activator domains in other proteins is used by additional viruses or other cell death stimuli as well.
Figure 5. Mutations in the latent Bak activator domain impair killing by Casp8p41 or HIV. (A and B) Flow cytometry data from Jurkat T cells transfected with empty vector or EGFP fused to Casp8p41, Casp8p41 V150A/L157A, Casp8p41 V150E/L157K, or procaspase 8 [Casp8] and stained 6 h later with Annexin V [A] or TUNEL [B]. Numbers on the top left indicate percentages of EGFP+ cells that are Annexin V or TUNEL positive. Representative of n = 3. (C and D) Pooled data from three independent experiments measuring Annexin V [C] or TUNEL [D] positivity in EGFP+ cells. Error bars indicate ±1 SD. [E] I9.2 cells transfected with EGFP, EGFP–procaspase 8, or EGFP–procaspase 8 C360S were infected with VSV-G–HIV-1, and the EGFP-positive cells were monitored for viability over time. [F] I9.2 cells reconstituted with EGFP fused to procaspase 8, procaspase 8 V150E/L157K, or procaspase 8 V150A/L157A were infected with VSV-G–HIV-1, and the EGFP-positive cells were monitored for cell viability over time. *, P < 0.05; **, P < 0.01 by linear regression. Error bars indicate SD.

Materials and methods

Plasmids and peptides

Casp8p41 and procaspase 8 were cloned into pEGFP-C1, pcDNA3-HA, or pGEX (Nie et al., 2008). BakΔTM (aa 1–186) was cloned into pGEX-4T-1 or pSPN (Dai et al., 2011). Mutations introduced using site-directed mutagenesis (Agilent Technologies) were confirmed by sequencing. The Casp8p41 activator peptide (DMNLDIEMEKRVIGKLD-IKRVCAG), Casp8p41 N-terminal control peptide (MDFSRELIDGIEQLD-SEDASLK), and Bim BH3 peptide (RPEIWIAGELREDNAYARKVF; Dai et al., 2011) were synthesized in the Mayo Clinic Proteomics Research Center.
Cell culture
Jurkat cells, the Jurkat variant I9.2 lacking procaspase 8, and 293T cells were obtained from American Type Culture Collection and cultured as instructed by the supplier. Fibroblasts from wt, Bak−/−, Bak+/−, and Bak−/−/Bak−/− mouse embryos were obtained from Z. Dong (Mayo Clinic, Augusta, GA). The Bak−/− mice were generated by deletion of exon 3–6 of the murine Bak, and the Bak+/− mice were generated by deletion of exons 2–4 and part of 5 of the murine Bax gene (Wei et al., 2001). In both cases, neomycin cassettes were inserted by homologous recombination.

Transfections and infections
Jurkat and I9.2 cells were transfected with 2 µg of DNA per 105 cells using a square wave electroporator (BXT) at 320 V or 40 mg of DNA per 105 cells at 240 V for 10 ms. HIV-1 infections were performed with a single-cycle reporter virus, HIV-1, which is vpu, vpr negative. HIV-1 was prepared in 293T cells by cotransfection with a VSV glycoprotein G (VSV-G) expression plasmid (3 µg of HIV-1 plasmid and 1 µg of VSV-G plasmid). I9.2 cells were infected with 30,000 pg of p24 (measured by p24 ELISA) per 105 cells for 3 h. Cells were then washed three times and incubated in fresh medium.

Lentiviral shRNA library screening
293T cells (105) were infected with a library containing 27,000 shRNAs in a lentiviral backbone encoding RFP (Cellctecta) at an MOI of 0.3–0.4. After 48 h, cells were selected with 1 µg/ml puromycin for 2 d. Surviving cells were then transfected with EGFP-Casp8p41 using Lipofectamine 2000. Beginning 48 h later, RFP/EGFP double-positive cells were collected by cell sorting and analyzed by Celllecta for the shRNA insert barcodes to enumerate shRNAs present.

Flow cytometry
Cell death was measured using Annexin V (BD), LIVE/DEAD fixable aqua dead cell stain (Invitrogen), or TUNEL (Roche) and analyzed on a FACScan flow cytometer (BD). All gating was set first to control samples and then applied to experimental samples.

Microscopy
For fluorescence microscopy, 293T cells were transfection overnight with GFP, GFF-Casp8p41, GFF-Casp8p41 V150A/L157A, or GFF-Casp8p41 V150E/L157K. Cells were then fixed with 2% paraformaldehyde for 1 h at room temperature and then permeabilized with PBS containing 0.1% Nonidet P-40 and 5% bovine serum albumin. Cells were first stained with Bak (Clone TC-100; EMD Millipore) antibody or mouse IgG control (BD), washed three times with PBS, and stained with a goat anti–mouse PE secondary antibody (BD) before being washed three times with PBS. Slides were prepared with DAPI containing Vectashield (Vector Laboratories). Laser scanning confocal microscopy was performed using a confocal laser scanning microscope (LSM 510; Carl Zeiss). Images were taken at the Mayo Microscopy and Cell Analysis Core facility.

Images were analyzed with KS400 Image Analysis Software (Carl Zeiss). The threshold value was determined and separately set for green and red fluorescence channels. The same threshold values were used for all subsequent images. Areas of green, red, and colocalized pixels were measured and data were expressed as a total percent area of green that colocalized with red.

Immunoprecipitation and immunoblotting
293T cells transfected with HA-empty vector, HA-Casp8p41, HA-Casp8p41 V150E/L157K, or HA-Casp8p41 V150A/L157A and pSPN-empt vector or pSPN-Bak expression vector for 24 h were collected, washed, and lysed. Cells were then incubated in 100 µl of lysis buffer (20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 2 µg/ml apronitin, 10 µg/ml leupeptin, 2 µg/ml pepstatin, and 1 mM PMSF) for 30 min on ice. His6-tagged proteins were purified using Ni2+-NTA-agarose (EMD Millipore). Alternatively, GST-tagged proteins were purified with glutathione-agarose (Thermo Fisher Scientific).

SPR
All proteins for SPR were further purified by fast protein liquid chromatography (FPLC) on Superdex S200, concentrated in a centrifugal concentrator (Centricron; EMD Millipore), dialyzed against Biacore buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.05 mM EDTA, and 0.005% [wt/vol] Polysorbate 20), and stored at 4°C for <48 h before use. Binding assays were performed at 25°C on a Biacore 3000 biosensor using GST-Casp8p41 or His6-BakΔTM immobilized on a CM5 chip (GE Healthcare). Ligands were injected at 30 µl/min for 1 min in Biacore buffer. Bound protein was eluted from the sensor chip by applying a solutions of Biacore buffer at 30 µl/min for 10 min and then desorbed with 2 M MgCl2. Binding kinetics were derived using BIA evaluation software (Biacore; GE Healthcare).

Preparation of FITC-Dextran lipid vesicles
1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphoethanolamine, 1,2-palmitoyldiacylglycerol, cholesterol, cardiolipin, and 18:1 DGS-NTA[Ni] at a weight ratio of 36:22:9:8:20:5 were dried as thin films in glass test tubes under nitrogen and then under vacuum for 16 h. 50 mg of FITC-labeled dextran 10 (F-d10; Molecular Probes) was encapsulated in lipid in 1 ml of 20 mM Hepes, 150 KCl, pH 7.0, by sonication followed by extrusion 15times through a 100-nm polycarbonate membrane. Gel filtration on Sephacryl S-300 HR (GE Healthcare) was used to remove untrapped F-d10. Phosphate was determined by colorimetric assay (Abcam).

Liposome release assay
Release of F-d10 from large unilamellar vesicles (LUVs) was monitored by fluorescence dequenching using a fluorimetric plate reader. Purified His6-Bak with or without other proteins was added to LUVs (final lipid concentration, 10 µg/ml in 96 well plates, which were then incubated at 37°C and monitored excitation, 485 nm; emission, 538 nm) every 10 s. The equation (Fsample − Fblank)/(Fsample − Fblank) × 100) was used to calculate F-d10 release, where Fsample, Fblank, and Fblank are fluorescent of reagent, buffer, and 1% Triton X-100-treated LUVs.

Analytical gel filtration
Purified His6-Bak and Casp8p41 proteins were mixed in CHAPS buffer (1% CHAPS, 1% glycerol, 150 mM NaCl, 5 mM DTT, and 20 mM Hepes, pH 7.5) at 23°C for 1 h. 200-µl samples were subjected to FPLC at 4°C on a Superdex S200 (GE Healthcare). Fractions (500 µl) were analyzed by SDS-PAGE followed by immunoblotting. Molecular markers (Sigma-Aldrich) in CHAPS buffer were run through the same column.

Cytchrome c release
Purified GST, GST-Casp8p41, or GST-Casp8p41 EK were dialyzed against mitochondria buffer (150 mM KCl, 5 mM MgCl2, 1 mM EGTA, and 25 mM Hepes, pH 7.5). Mitochondria purified from wt, Bak−/−, Bak−/−, or Bak−/−/Bak−/− MEFs were incubated with the indicated proteins at 23°C for 1 h. After centrifugation (10,000 g for 15 min), supernatants and pellets were analyzed by immunoblotting.

Clinical HIV samples
Blood was obtained from five HIV-infected, viremic patients according to a Mayo Clinic Institutional Review Board approved protocol. After patients signed informed consent, peripheral blood mononuclear cells were isolated by Ficoll gradient, fixed with 4% paraformaldehyde, permeabilized with PBS containing 0.1% Nonidet P-40 and 5% bovine serum albumin, and stained with a monoclonal antibody specific for Casp8p41 directly conjugated with Mixx-Stain CF 640R (Sigma-Aldrich) overnight at 4°C.
Cells were co-cultured with 1 μM recombinant DsRed-Bak and monitored for 3 d after infection. The percentage of cells exhibiting red fluorescence was assessed using a fluorescence microscope.

Discussion

We show here that the Bak activator domain may be exploited to deliver proapoptotic BH3-agents to target cancer cells. A key feature of our approach is the use of the RAB-MAPK pathway as a recombinant platform to express recombinant Bak activator domain.

Experimental procedures

Materials

Recombinant protein expression and purification

All recombinant proteins were expressed in Escherichia coli, purified using standard procedures, and used in experiments without further purification. For experiments involving recombinant Bak activator domain expressed in E. coli, the recombinant protein was purified using standard procedures, and used in experiments without further purification. For experiments involving recombinant Bak activator domain expressed in E. coli, the recombinant protein was purified using standard procedures, and used in experiments without further purification.

Results

We show here that the Bak activator domain may be exploited to deliver proapoptotic BH3-agents to target cancer cells. A key feature of our approach is the use of the RAB-MAPK pathway as a recombinant platform to express recombinant Bak activator domain.

Conclusion

In conclusion, our results suggest that the Bak activator domain may be exploited to deliver proapoptotic BH3-agents to target cancer cells. A key feature of our approach is the use of the RAB-MAPK pathway as a recombinant platform to express recombinant Bak activator domain.

Online supplemental material

Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201405051/DC1.
of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782–6786.

Kim, H., H.C. Tu, D. Ren, O. Takeuchi, J.R. Jeffers, G.P. Zambetti, J.H. Hsieh, and E.H. Cheng. 2009. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell. 36:487–499. http://dx.doi.org/10.1016/j.molcel.2009.09.030

Kuwana, T., L. Bouchier-Hayes, J.E. Chipuk, C. Bonzon, B.A. Sullivan, D.R. Green, and D.D. Newmeyer. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 17:525–535. http://dx.doi.org/10.1016/j.molcel.2005.02.003

Letai, A., M.C. Bassik, L.D. Walensky, M.D. Sorcinelli, S. Weiler, and S.J. Korsmeyer. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:183–192. http://dx.doi.org/10.1016/S1535-6108(02)00127-7

Llambi, F., T. Moldoveanu, S.W. Tait, L. Bouchier-Hayes, J. Temirov, L.L. McCormick, C.P. Dillon, and D.R. Green. 2011. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell. 44:517–531. http://dx.doi.org/10.1016/j.molcel.2011.10.001

Miller, L.K. 1999. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 9:323–328. http://dx.doi.org/10.1016/S0962-8924(99)01609-8

Moldoveanu, T., C.R. Grace, F. Llambi, A. Nourse, P. Fitzgerald, K. Gehring, R.W. Kriwacki, and D.R. Green. 2013. BID-induced structural changes in BAK promote apoptosis. Nat. Struct. Mol. Biol. 20:589–597. http://dx.doi.org/10.1038/nsmb.2563

Natesampillai, S., Z. Nie, N.W. Cummins, D. Joehmans, G.D. Bren, J.B. Angel, and A.D. Badley. 2010. Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. PLoS Pathog. 6:e1001213. http://dx.doi.org/10.1371/journal.ppat.1001213

Nie, Z., B.N. Phenix, J.J. Lum, A. Alam, D.H. Lynch, B. Beckett, P.H. Krammer, R.P. Sekaly, and A.D. Badley. 2002. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage, and nuclear fragmentation. Cell Death Differ. 9:1172–1184. http://dx.doi.org/10.1038/sj.cdd.4401094

Nie, Z., G.D. Bren, S.A. Rizza, and A.D. Badley. 2008. HIV protease cleavage of procaspase 8 is necessary or death of HIV-infected cells. Open Virol. J. 2:1–7. http://dx.doi.org/10.2174/1874357900802010001

Pang, Y.-P., H. Dai, A. Smith, X.W. Meng, P.A. Schneider, and S.H. Kaufmann. 2012. Bak conformational changes induced by ligand binding: Insight into BH3 domain binding and Bak homo-oligomerization. Sci. Rep. 2:257. http://dx.doi.org/10.1038/srep00257

Pearlman, D.A., D.A. Case, J.W. Caldwell, W.S. Ross, T.E. Cheatham III, W. Wu, S., and Y. Zhang. 2008. MUSTER: Improving protein sequence profile alignments by using multiple sources of structure information. Proteins. 72:547–556. http://dx.doi.org/10.1002/prot.21945

Yu, J.W., P.D. Jeffrey, and Y. Shi. 2009. Mechanism of procaspase-8 activation by c-FLIPL. Proc. Natl. Acad. Sci. USA. 106:8169–8174. http://dx.doi.org/10.1073/pnas.0812453106

Downloaded from jcb.rupress.org on August 15, 2017